← Back to Analyst Consensus 
COAG Buy
Hemab Therapeutics Holdings, Inc.
Current Price —
Implied Upside —
Analysts 11
30-Day Momentum
▲ 2 upgrades / ▼ 0 downgrades / 0 reiterations from 2 firms
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 15, 2026 | JP Morgan | initiate | — → Overweight | — | 54% |
| Oct 12, 2026 | Rodman & Renshaw | initiate | — → Buy | — | 40% |
| Aug 12, 2026 | Wedbush | maintain | Outperform → Outperform | — | 57% |
| Aug 11, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Jul 13, 2026 | Jefferies | maintain | Buy → Buy | — | 52% |
| Jul 13, 2026 | Wedbush | maintain | Outperform → Outperform | — | 57% |
| Jul 13, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Jun 26, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Jun 17, 2026 | HC Wainwright & Co. | initiate | — → Buy | — | 44% |
| May 26, 2026 | Wedbush | initiate | — → Outperform | — | 57% |
| May 26, 2026 | Jefferies | initiate | — → Buy | — | 52% |
| May 26, 2026 | Evercore ISI Group | initiate | — → Outperform | — | 58% |
| May 26, 2026 | Goldman Sachs | initiate | — → Buy | — | 54% |
Price Target Trend
Jun 4, 2026 Oct 27, 2026
EPS Estimates
+1y —
+1q —
0y —
0q —
Cross-Platform Signals
No cross-platform signals in the last 90 days